Determination of the anticonvulsant felbamate and its three metabolites in brain and heart tissue of rats

Determination of antiepileptic drugs in biological material

Current analytical methodologies applied to the determination of antiepileptic drugs in biological material are reviewed. The role of chromatographic techniques is emphasized. Special attention is focused on new chemical entities as well as current trends such as high-speed liquid chromatographic techniques, hyphenated techniques and electrochromatography techniques. A review with 542 references.

Determination of felbamate concentration in pediatric samples by high-performance liquid chromatography

A simple and rapid procedure to determine felbamate (2-phenyl-1,3-propanediol dicarbamate) concentrations in human plasma/serum by high-performance liquid chromatography is described. The method employs a high-performance liquid chromatography unit equipped with a C18 reverse-phase cartridge (3-microliters particle diameter, 3.2 x 40 mm), an acetonitrile/water gradient, and detection at 210 nm. The sample is deproteinized with acetonitrile containing internal standard (2-methyl-2-phenyl-1,3-propanediol dicarbamate), and the resulting supernatant, after diluting 1:1 with water, is injected onto the column. The felbamate and internal standard are eluted with a linear gradient of 0% to 22% acetonitrile for 11 minutes at a flow rate of 0.8 ml/minute. Under these conditions, felbamate and the internal standard are eluted at 9.2 +/- 0.03 and 10.8 +/- 0.03 minutes, respectively. The assay is linear from 10 to 400 microgram/ml. It is highly reproducible; at 100 micrograms/ml felbamate, within-day and between-day coefficients of variation are less than 0.5% and 4.3%, respectively. Recovery is > or = 95%. No interferences from other common antiepileptic drugs and analgesics are observed. Advantages of this method include simple and fast sample preparation; use of a gradient to eliminate interferences; and use of a cartridge column, which is economical, provides good resolution, allows rapid equilibration and elution, and operates at low back pressures. The method requires samples of only 100 microliters and is ideal for pediatric samples.

Totally automated analysis by robotized PrepStation and liquid chromatography: direct-sample analysis of felbamate

A totally automated analysis of felbamate was developed by using a robotized PrepStation for extraction, followed by automated liquid chromatographic (LC) analysis and data reduction. This is one of the newer direct-sample analysis approaches by LC. Felbamate was a previously approved antiepileptic agent used to treat partial seizures with and without generalization and to treat Lennox-Gastaut syndrome in pediatric patients. However, due to the reported incidences of aplastic anemia, its clinical application was recently restricted to the treatment of the latter syndrome. The automated assay using Bench Supervisor, PrepStation, and LC, based on a previously developed manual method, used 200 microliters of serum standards, quality control, or patients' plasma. These were mixed with 600 microliters of internal standard (IS) W509 dissolved in acetonitrile for protein precipitation. After axial centrifugation and standing, aliquots of the clear supernatant were transferred and washed with hexane. Aliquots of the supernatant were transferred and injected into a high-performance liquid chromatograph (HPLC). HPLC parameters included an mu Bondapak C-18 column, phosphate/acetonitrile (8:2) as mobile phase, and detection at 214 nm. Retention times were 2.9 and 4.2 min for felbamate and IS, respectively. Calibration was linear for concentrations from 10 to 200 mg/L with r > 0.994. Precision studies showed coefficients of variation ranging from 2.7% to 8.8%. Correlation with the manual method showed that r = 0.934, slope = 1.048, intercept = -2.642, and n = 21. Phenobarbital coeluted with the IS. This study demonstrated the feasibility of using a robotized, automated method for monitoring felbamate, readily extended to monitoring other antiepileptic drugs with minimal modification.

Felbamate

After the first year of clinical experience, felbamate (FBM) appears to be a valuable antiepileptic drug (AED) for the treatment of intractable epilepsy. However, many patients experience side effects that may discourage continued usage. These may be decreased by using a slower dose-escalation schedule and/or by being more aggressive in decreasing co-medication. The most common troublesome side effects are nausea and insomnia. With the recent observation of aplastic anemia, FBM should be considered only for persons with intractable epilepsy under the care of a physician familiar with FBM. Nevertheless, many patients have benefited significantly from FBM and have made a decision to continue receiving FBM at the presently known risk profile. A few more years of experience may be needed to more accurately determine the final place of FBM in the treatment of epilepsy.

Simultaneous determination of felbamate and four metabolites in rat cerebrospinal fluid by high-performance liquid chromatography

An isocratic liquid chromatographic method for direct sample injection has been developed for the quantitation of felbamate and four metabolites in rat cerebrospinal fluid. The method uses 0.050- or 0.025-ml aliquots of cerebrospinal fluid diluted with equal volumes of internal standard. Chromatography is performed on a 150 mm x 4.6 mm I.D. Spherisorb ODS2, 3-microns HPLC column eluted with a phosphate buffer-acetonitrile-methanol (820:120:60, v/v/v) mobile phase and ultraviolet absorbance detection at 210 nm. The linear quantitation ranges are: felbamate and the 2-hydroxy metabolite 0.195-200 micrograms/ml, the propionic acid metabolite 0.195-50.0 micrograms/ml, the p-hydroxy metabolite 0.781 to 50.0 micrograms/ml, and the monocarbamate metabolite 0.098-50.0 micrograms/ml.